• Users Online: 225
  • Print this page
  • Email this page
Year : 2020  |  Volume : 24  |  Issue : 2  |  Page : 99-104

Clinical and epidemiological profile of libyan patients with mycosis fungoides: A prospective study

1 Department of Dermatology, Faculty of Medicine, Benghazi University, Benghazi, Libya
2 Department of Histopathology, Benghazi Medical Center, Benghazi, Libya

Correspondence Address:
Dr. Nadia A El Sherif
Department of Dermatology, Faculty of Medicine, Benghazi University, Benghazi
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jdds.jdds_24_20

Get Permissions

Background: Mycosis fungoides (MF) represents the most common form of primary cutaneous T-cell lymphoma (CTCL) often with an indolent course. Purpose: The objective is to determine epidemiological and clinical features of MF among Libyan patients. Methods: Clinical and histopathological evaluation was carried out in 24 patients with MF in the Department of Dermatology at El-Jumhoria Hospital in Benghazi city between 2010 and 2019. Results: Twenty-four patients with a diagnosis of MF, 11 were female and 13 were male. Age of the patients ranged between 30 and 60 year with a mean of age ± standard deviation of 47.4 ± 8 years. Clinical presentation with patches and plaques was most common, seen in 58.3% of the patients. Poikilodermatous MF was seen in 37.5% patients, hypopigmented MF seen in 12.5% of patients, follicular MF seen in 8.3% of patients, and 8.3% patients had lymphomatoid papulosis. Pruritis was the complaint of 75% of the patients. About 25% of the patients had blood eosinophilia, 33.3% had raised lactic dehydrogenase enzyme. Tumor-node-metastasis-blood (TNMB) classification of the patients revealed that 66.7% had stage IB, 20.8% of patients had stage IIA, 8.3% of patients had stage IIB, and 4.2% patients had stage IVa. About 70.8% of patients received systemic Psoralen and ultraviolet A (PUVA) therapy, 20.8% patients received narrow band ultraviolet B, 4.2% patients treated with radiotherapy, and 4.2% patients received both chemotherapy and radiotherapy. About 45.8% of patients show remission of their disease, 12.5% patients show no response, 8.3% of patients still under treatment, 25% of patients lost follow-up, and 8.3% patients died. Conclusion: MF is a low-grade primary CTCL with different clinical presentations with variable response to therapy.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded77    
    Comments [Add]    

Recommend this journal